THE FUTURE OF WOMEN'S HEALTH IS HERE!
Revisit our fireside chat with Portfolia Investor, Startup Advisor and Entrepreneur, Anna Zornosa and Femtech III Lead Partner, Top attorney specializing in women's health Delphine O'Rourke. In a year overshadowed by setbacks in reproductive rights, Anna highlights the remarkable strides made in various facets of women's health that deserve celebration, painting a surprisingly optimistic picture of the state of women's health in 2023 and on.
ABOUT FEMTECH
Portfolia is the most active investor in women's health in the US, with a total of 46 investments in healthcare companies, from seed stage to pre-IPO. Investments include early-stage companies like Bone Health and Your Choice to fast scaling brand-name companies, like unicorns Everly Health and Maven Clinic. The Portfolia FemTech III Fund builds on Portfolia’s global brand in women health, optimizing returns and enhancing the health and wellness of women.
Portfolia closed the world's first venture capital fund focused exclusively in women's health in 2018. Our current portfolio is strong and scaling. We have a robust pipeline with growing opportunities in women's health, across all stages.
OUR FEMTECH III INVESTMENTS
FOCUS AREAS
Portfolia goes beyond, the obvious investments in menstrual care, fertility solutions and pregnancy care have received the most significant investments, into all facets of women's health and wellness at every stage of life. Portfolia will consider companies in the following areas, but not limited to:
-
Contraception, Fertility, Maternal Health, Menopause, Gynecology & Women’s Oncology
-
Cardiovascular Disease, Diabetes, Alzheimer’s Disease
-
Autoimmune Disease, Osteoporosis, Anxiety and Depression, Lung Cancer
-
Pain, Behavioral Health
-
Conditions that affect women of color differently, access to care, quality of care, lack of culturally competent care providers, systemic racism
LEAD PARTNERS
An anchor tenet of venture capital when evaluating investments is that it is always about the team. In the case of FemTech III, the partners are the most experienced investors in women’s health, across stages and specialty focus, and the fund is recognized as a global expert in this space.
Collectively this competitive advantage means:
Deep and rich sourcing networks bringing a robust pipeline of women entrepreneurs and their growing company.
A global network of business building experts across every stage and specialty field in fast growth entrepreneurship
Vast global intelligence for due diligence and decision-making, and an early-warning system for competition and problem solving
Predictive knowledge regarding emerging needs as entrepreneurs scale their companies, resulting in better strategies, hiring and fundraising
Advisory assistance and C-suite and team coaching
WHY INVEST IN FEMTECH III NOW?
Today women’s health is recognized as the most majority of healthcare investors are men, most of whom have little understanding of the significant gaps or opportunities to enhance women’s health. The lack of investment means new innovations that could be brought to market are overlooked or misunderstood. This translates into compromised health and wellness for all women.
314% Increase in women’s health VC investment since 2018
2023 is on pace to become a top three funding year for the women's health sector.
$435M Investments in non-fertility startups in Q3 2023
This single quarter record shows a heartening shift in the long-held misconception that fertility and pregnancy are the sole focus of women’s health.
76% Of women’s health companies have a female founder
This rate is three times higher than the overall innovation ecosystem.